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IMPORTANCE Secondary hyperparathyroidism contributes to extraskeletal complications in
chronic kidney disease.
OBJECTIVE To evaluate the effect of the intravenous calcimimetic etelcalcetide on serum
parathyroid hormone (PTH) concentrations in patients receiving hemodialysis.
DESIGN, SETTING, AND PARTICIPANTS Two parallel, phase 3, randomized, placebo-controlled
treatment trials were conducted in 1023 patients receiving hemodialysis with moderate to
severe secondary hyperparathyroidism. Trial A was conducted in 508 patients at 111 sites in
the United States, Canada, Europe, Israel, Russia, and Australia fromMarch 12, 2013, to June
12, 2014; trial B was conducted in 515 patients at 97 sites in the same countries fromMarch 12,
2013, to May 12, 2014.
INTERVENTIONS Intravenous administration of etelcalcetide (n = 503) or placebo (n = 513)
after each hemodialysis session for 26 weeks.
MAIN OUTCOMES ANDMEASURES The primary efficacy end point was the proportion of
patients achieving greater than 30% reduction from baseline in mean PTH during weeks
20-27. A secondary efficacy end point was the proportion of patients achieving mean PTH of
300 pg/mL or lower.
RESULTS Themeanageof the 1023patientswas58.2 (SD, 14.4) years and60.4%weremen.
MeanPTHconcentrations at baseline andduringweeks20-27were849and384pg/mLvs820
and897pg/mL in theetelcalcetide andplacebogroups, respectively, in trial A; corresponding
valueswere845and363pg/mLvs852and960pg/mL in trial B. Patients randomized to
etelcalcetidewere significantlymore likely to achieve theprimary efficacy endpoint: in trial A, 188
of 254 (74.0%)vs21 of 254 (8.3%;P < .001), for adifference inproportionsof65.7%(95%CI,
59.4%-72.1%) and in trial B, 192of 255 (75.3%)vs25of 260 (9.6%;P < .001), for adifference in
proportionsof65.7%(95%CI, 59.3%-72.1%). Patients randomized toetelcalcetidewere
significantlymore likely to achieve aPTH level of 300pg/mLor lower: in trial A, 126of 254
(49.6%)vs 13of 254 (5.1%;P < .001), for adifference inproportionsof44.5%(95%CI, 37.8%-
51.2%) and in trial B, 136of 255 (53.3%)vs 12of 260 (4.6%;P < .001), for adifference in
proportionsof48.7%(95%CI, 42.1%-55.4%). In trials A andB, respectively, patients receiving
etelcalcetidehadmoremuscle spasms (12.0%and 11.1%vs 7.1%and6.2%withplacebo), nausea
(12.4%and9.1%vs5.1%and7.3%), andvomiting (10.4%and7.5%vs7.1%and3.1%).
CONCLUSIONS AND RELEVANCE Among patients receiving hemodialysis withmoderate to
severe secondary hyperparathyroidism, use of etelcalcetide compared with placebo resulted
in greater reduction in serum PTH over 26 weeks. Further studies are needed to assess
clinical outcomes as well as longer-term efficacy and safety.
TRIAL REGISTRATION clinicaltrials.gov Identifiers: NCT0178584, NCT01788046
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S econdaryhyperparathyroidism is an important compli-cation of chronic kidney disease (CKD), particularlyamong patients receiving hemodialysis. Elevated se-
rum concentrations of parathyroid hormone (PTH) contrib-
ute toboneandcardiovascular disorders (includingosteitis fi-
brosa cystica and calcific cardiovascular disease, broadly
referred to asCKD–mineral bonedisorder), alongwithmyopa-
thy, neuropathy, anemia, and pruritus, and have been inde-
pendently associated with all-cause and cardiovascular
mortality.1,2 Current treatment options consist of oral admin-
istration of intestinal phosphate binders, oral or intravenous
calcitriol or active vitamin D analogs, and the oral calcimi-
metic agent cinacalcet. These interventions are often limited
by undesirable off-target or adverse effects and several re-
quire adherence to daily or thrice-daily oral ingestion.
Etelcalcetide is a syntheticpeptidecomposedof7D-amino
acids linked to an L-cysteine via a disulfide bond that func-
tions as an activator of the calcium-sensing receptor. Single
doses of etelcalcetide have been shown to reduce PTH in
healthy volunteers3 and patients with end-stage renal dis-
ease receiving hemodialysis.4 A single 12-week phase 2 dose
escalation study of etelcalcetide in 37 patients receiving he-
modialysis resulted in sustained reductions in PTH, calcium,
and phosphate.5
Herein we report the combined results of 2 parallel,
phase 3, randomized, placebo-controlled multinational
trials designed to assess the safety and efficacy of etelcal-
cetide in patients receiving hemodialysis with inadequately
controlled secondary hyperparathyroidism.
Methods
The trialswere approvedby institutional reviewboards at par-
ticipating study sites and all patients provided written in-
formed consent. Trial protocols are available in Supplement 1
and Supplement 2.
Participants
Patients receiving thrice-weekly maintenance hemodialysis
withmoderate to severe secondaryhyperparathyroidism(PTH
>400 pg/mL) with albumin-corrected serum calcium of
8.3mg/dLorhigher and taking stabledosesof calciumsupple-
ments or phosphate binders and calcitriol or active vitaminD
analogswere eligible for randomization. A complete list of in-
clusion and exclusion criteria is available in the eAppendix in
Supplement 3. Race and ethnicity data were obtained to as-
sess generalizability to clinical practice andwere determined
by self-report using fixed categories (white, black or African
American, Asian, Native Hawaiian or Pacific Islander, and
American IndianorAlaskaNative). Eligible patients couldnot
have received cinacalcet during the 4 weeks prior to the first
screening laboratory assessments, andcinacalcet therapywas
prohibited during the study.
Study Design
Both clinical trials were 26-week, phase 3, multicenter, ran-
domized, double-blind, placebo-controlled trials. All
patients, regardless of treatment assignment, received stan-
dard of care with phosphate binders and calcitriol or active
vitamin D analogs as prescribed by the individual investiga-
tor. The trials were identical, as required for regulatory
approval, with the exception that predialysis and postdialy-
sis laboratory data and electrocardiograms were obtained in
trial A, whereas only predialysis measurements were per-
formed in trial B.
Procedures
Eligible patients were randomized 1:1 to receive either pla-
cebo or etelcalcetide by an interactive voice/web response
system. Permuted block randomization with a block size of
4 was used, stratified by geographic region, prior cinacalcet
use within 8 weeks of randomization, and screening PTH
level. Study drug (etelcalcetide or placebo) was adminis-
tered via bolus injection into the venous line of the dialysis
circuit, immediately prior to or during rinse-back after each
hemodialysis session for 26 weeks. The starting dose was 5
mg and could be increased in 2.5-mg or 5-mg increments at
weeks 5, 9, 13, and 17 based on PTH and calcium results
obtained during the prior week to achieve predialysis PTH
of 300 pg/mL or lower, to a maximum dose of 15 mg. Inves-
tigators were blinded to PTH and phosphate results. Study
drug was temporarily withheld for low PTH (<100 pg/mL
on 2 consecutive measurements), low serum (albumin-
corrected) calcium (<7.5 mg/dL), or symptomatic hypocalce-
mia and was subsequently resumed at a reduced dose.
Investigators remained blinded to conditions that required
etelcalcetide dose suspension, as the interactive voice/web
response system algorithm randomly selected a matched
patient receiving placebo in whom to suspend dosing. Sites
were instructed to suspend routine local PTH monitoring
during the study. Sites were not blinded to serum calcium
levels to ensure the safety of trial participants.
Biochemical and Other Determinations
Biochemical data were collected prior to hemodialysis at
baseline and periodically (eg, calcium and phosphate weekly,
PTH every 2 weeks) through week 27 and analyzed in central
Key Points
Question What is the effect of the intravenous calcimimetic
etelcalcetide compared with placebo on serum parathyroid
hormone concentrations in patients receiving hemodialysis?
Findings In 2 randomized clinical trials that included 1023 adults
receiving hemodialysis with moderate to severe secondary
hyperparathyroidism, patients randomized to etelcalcetide
compared with placebo were significantly more likely
to have a greater than 30% reduction in mean parathyroid
hormone concentrations over 26 weeks (74.0% vs 8.3% and
75.3% vs 9.6%).
Meaning Etelcalcetide wasmore effective than placebo in
lowering parathyroid hormone concentration in patients receiving
dialysis with secondary hyperparathyroidism, but further research
is needed to assess clinical outcomes as well as longer-term
efficacy and safety.
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laboratories. Parathyroid hormone was analyzed in serum
samples using the Advia Centaur assay (Covance; population
reference range, 14-72 pg/mL). Serum bone-specific alkaline
phosphatase, collagen type 1 cross-linked C-telopeptide, and
intact fibroblast growth factor 23 (FGF23) were also mea-
sured, the latter using the Kainos ELISA kit (Medpace) on day
1 (before dosing) and at weeks 12 and 27. Triplicate electro-
cardiograms were acquired using standardized equipment
and analyzed in a blinded fashion by an independent agency
(eResearch Technology) at screening, day 1, and weeks 5, 13,
and 26; QT intervals were corrected for heart rate using the
formulas of Bazett (QTcB) and Fridericia (QTcF).
Outcomes
The primary efficacy end point was the proportion of
patients with greater than 30% reduction from baseline in
mean PTH during the efficacy assessment phase (weeks
20-27). The primary end point for these trials was chosen in
agreement with the US Food and Drug Administration.
Although no published data specifically document overt
clinical benefits related to a 30% or greater reduction of
PTH, several observational studies have shown that PTH
concentrations greater than 600 pg/mL are associated
with higher rates of death, cardiovascular events, and frac-
ture than PTH concentrations in the range of 150 to 300
pg/mL.6-9 Secondary end points included the proportion of
patients with mean PTH levels of 300 pg/mL or lower and
percentage reductions in PTH, calcium, calcium × phos-
phate, and phosphate. Exploratory end points included
change in FGF23 and the bone turnover markers of bone-
specific alkaline phosphatase and collagen type 1 cross-
linked C-telopeptide.
Statistical Analysis
We estimated that treatment with placebo would result in a
greater than 30% reduction in PTH in less than 20% of
patients based on experience from an earlier phase 2 trial.5 In
the same phase 2 trial, the response rate for patients treated
with etelcalcetide was 54%. For each trial, we assumed that
10% of randomized patients would not receive study drug
and 25% of randomized patients would drop out before the
efficacy assessment phase. We estimated response rates of
35% for etelcalcetide and 20% for placebo based on data from
phase 2 clinical trials with etelcalcetide.4,5 For a condition in
which the majority of patients do not achieve control, a 15%
absolute increase in the proportion of patients achieving con-
trol (corresponding to a 75% relative increase) was deemed
clinically important. A sample size of 250 in each treatment
group would yield at least 90% power to detect a difference
in the primary efficacy end point using a χ2 test with a
2-sided statistical significance level of .05.
All data were analyzed according to the intention-to-treat
principle. Where applicable, analyses were adjusted for
stratification factors. The primary and secondary efficacy
end points for the proportion of patients achieving PTH lev-
els of 300 pg/mL or lower were analyzed using the Cochran-
Mantel-Haenszel χ2 statistic. Patients with no PTH data dur-
ing the efficacy assessment phase were included in all
analyses and were considered to be nonresponders. Second-
ary efficacy end points for percentage change from baseline
were analyzed using a repeated-measures mixed-effects
model. To control for the study-wise type 1 error rate, the sec-
ondary efficacy end points were analyzed only after the pri-
mary efficacy end point reached the prespecified level of sig-
nificance. Secondary efficacy end points were analyzed in
the sequence listed above. Two-sided P<.05 was considered
statistically significant. All statistical analyses were con-
ducted using SAS version 9.3 (SAS Institute Inc).
Results
Trial Awas conducted in 508patients at 111 sites in theUnited
States, Canada, Europe, Israel, Russia, and Australia from
March 12, 2013, to June 12, 2014; trial B was conducted in 515
patients at 97 sites in the same countries fromMarch 12, 2013,
toMay 12, 2014. The disposition of trial participants is shown
in Figure 1. The proportion of randomized patients by coun-
try is described in eTable 1 in Supplement 3.
Table 1 shows selected baseline demographic and clinical
data for patients by randomized treatment group. The mean
age was 58.2 (SD, 14.4) years and 60.4% were men. Baseline
characteristics were similar across trials except that in trial A,
more patients were using hemodiafiltration rather than
hemodialysis (16.1% vs 12.8%) and fewer patients were using
low (<2.5 mEq/L) baseline dialysate calcium concentrations
(6.1% vs 10.1%) relative to trial B. Baseline characteristics of
the etelcalcetide and placebo groups were well balanced
across both trials.
Mean percentage change in serum PTH and mean change
in serum calcium and phosphate concentrations over
time are shown in Figure 2. In trial A, mean PTH concentra-
tions were 849 and 384 pg/mL at baseline and vs 820 and
897 pg/mL during the efficacy assessment phase in the
etelcalcetide and placebo groups, respectively; correspond-
ing values in trial B were 845 and 363 pg/mL vs 852 and
960 pg/mL. Patients randomized to etelcalcetide were sig-
nificantly more likely than those in the placebo group,
respectively, to achieve the primary efficacy end point (for
trial A: 188/254 [74.0%] vs 21/254 [8.3%; P < .001]; difference
in proportions, 65.7% [95% CI, 59.4%-72.1%]; for trial B,
192/255 [75.3%] vs 25/260 [9.6%; P < .001]; difference in pro-
portions, 65.7% [95% CI, 59.3%-72.1%]). Sixty patients in trial
A (11.8%) and 51 patients in trial B (9.9%) contributed no PTH
data during the efficacy assessment phase and were consid-
ered nonresponders. A secondary PTH-based efficacy end
point (the proportion of patients achieving mean PTH levels
≤300 pg/mL) was also achieved (for trial A: 126/254 [49.6%]
with etelcalcetide vs 13/254 [5.1%] with placebo [P < .001];
difference in proportions, 44.5% [95% CI, 37.8%-51.2%]; for
trial B: 136/255 [53.3%] with etelcalcetide vs 12/260 [4.6%]
with placebo [P < .001]; difference in proportions, 48.7%
[95% CI, 42.1%-55.4%]). More than half of etelcalcetide-
treated patients achieved greater than 30% reduction in PTH
in less than 6 weeks (eFigure 1 in Supplement 3). The differ-
ence in proportions of patients achieving greater than 30%
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reduction in PTH was similar across all patient subgroups
(eFigure 2 in Supplement 3). Median per-session dose of
etelcalcetide during the efficacy assessment phase was 7.1 mg
(interquartile range, 3.6-10.0 mg) in trial A and 5.0 mg (inter-
quartile range, 2.5-10.0 mg) in trial B. The distribution of
study drug dose received over the course of each trial is
shown in eTable 2 in Supplement 3.
eFigure 3 in Supplement 3 shows changes in the use of
calcium supplements or calcium-containing phosphate
binders and calcitriol or active vitamin D analogs in both
trials. The proportion of patients receiving calcium supple-
ments or calcium-containing phosphate binders and the
proportion of patients receiving active vitamin D analogs
increased in the etelcalcetide group. eTable 3 in Supplement
3 shows dialysate calcium concentrations at baseline and
end of study by randomized group; 37% and 51% of patients
treated with etelcalcetide were treated with dialysate cal-
cium concentrations greater than 2.5 mEq/L at the end of
trials A and B, respectively.
Exploratory End Points
Treatment with etelcalcetide decreased serum intact FGF23.
Figure 3 shows serum intact FGF23 concentrations at base-
line, week 12, and week 27 and Figure 4 shows median per-
centage change in serum intact FGF23 at weeks 12 and 27 by
randomized group within each trial.
Treatment with etelcalcetide decreased bone-specific
alkaline phosphatase and collagen type 1 cross-linked
C-telopeptide. eTable 4 in Supplement 3 shows median abso-
lute and percentage changes in bone-specific alkaline phos-
phatase and collagen type 1 cross-linked C-telopeptide at
weeks 12 and 27 by randomized group within each trial.
Adverse Events
Reductions in serum calcium were the most frequent
adverse events. eTable 5 in Supplement 3 shows the propor-
tion of patients with serum calcium concentrations below 3
thresholds.
Treatment-emergent death occurred in 7 of 251 patients
(2.8%) in trial A and 4 of 252 patients (1.6%) in trial B who re-
ceived at least 1 dose of etelcalcetide vs 7 of 254 (2.8%) and 8
of 259 (3.1%) who received placebo, respectively. Among pa-
tients treated with etelcalcetide, adjudicated positive myo-
cardial infarctionoccurred in8 (3 [1.2%] in trial A and5 [2.0%]
in trial B), stroke in 2 (1 [0.4%] in each trial), and hospitaliza-
tion for heart failure in 11 (7 [2.8%] in trial A and 4 [1.6%] in
trialB).Amongpatients in theplacebogroup,adjudicatedposi-
tivemyocardial infarctionoccurred in5 (2 [0.8%] in trialA and
3 [1.2%] in trial B), stroke in 3 (1 [0.4%] in trial A and 2 [0.8%]
in trial B), and hospitalization for heart failure in 6 (2 [0.8%]
in trial A and 4 [1.5%] in trial B). Confirmed seizures occurred
in 4 patients (2 [0.8%] in each treatment group) in trial A and
6 (3 [1.2%] in each group) in trial B. Table 2 shows a full list of
adverse events with a frequency of at least 5% with at least a
1%differencebetween treatment groups.Amore comprehen-
sive listofadverseevents isprovided ineTable6 inSupplement
3;eTable7showsbaselineandmaximalpredialysisQTcB,QTcF,
and maximal changes from baseline.
Discussion
These trials have several strengths. Participants were diverse
in termsofage, sex, race, geographic region, andprimarycause
of end-stage renal disease andhadabroad rangeof comorbid-
ity and severity of secondary hyperparathyroidism. Few pa-
tientswere lost to follow-up and relatively few stopped study
drug for non–protocol-specified reasons. In aggregate, 74.7%
Figure 1. Participant Flow in 2 Trials Assessing the Effect of Etelcalcetide
vs Placebo on SerumParathyroid Hormone Concentrations in Patients
Receiving HemodialysisWith Secondary Hyperparathyroidism
Trial A
840 Patients screened
332 Excluded (did not meet
inclusion criterion)a
508 Randomized
254 Randomized to etelcalcetide
251 Received etelcalcetide as
randomized
3 Did not receive etelcalcetide
254 Randomized to placebo
254 Received placebo as
randomized
254 Included in analysis of primary
outcome
254 Included in analysis of primary
outcome
220 Completed study
34 Discontinued study
11 Lost to follow-up
9 Died
1 Decision by sponsor
1 Protocol-specified criteriab
12 Withdrew consent
193 Completed study
61 Discontinued study
15 Withdrew consent
10 Lost to follow-up
7 Died
29 Protocol-specified criteriab
Trial B
825 Patients screened
310 Excluded (did not meet
inclusion criterion)a
515 Randomized
255 Randomized to etelcalcetide
252 Received etelcalcetide as
randomized
3 Did not receive etelcalcetide
260 Randomized to placebo
259 Received placebo as
randomized
1 Did not receive placebo
255 Included in analysis of primary
outcome
260 Included in analysis of primary
outcome
218 Completed study
37 Discontinued study
12 Withdrew consent
5 Died
1 Protocol-specified criteriab
19 Lost to follow-up
204 Completed study
56 Discontinued study
12 Withdrew consent
12 Lost to follow-up
7 Died
25 Protocol-specified criteriab
a Specific reasons not available.
b Participants met discontinuation criteria for increasing parathyroid hormone
levels after week 12.
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of patients randomized to receive the intravenous calcimi-
metic etelcalcetide thrice weekly after hemodialysis experi-
encedgreater than30%reduction inserumPTHcomparedwith
less than 8.9%of patients randomized to placebo. The reduc-
tion in PTH was rapid, sustained over 26 weeks, and evident
in all evaluated subgroups, with no apparent effectmodifica-
tion by age, sex, race, time since dialysis initiation, geo-
graphic region, baseline severity of secondary hyperparathy-
roidism, or use of vitamin D. The wide range of doses used
in the trials demonstrates the importance of using a dose-
titration strategy rather than a fixed dose for all patients. The
efficacy results are particularly noteworthy given that pa-
tients were already receiving conventional therapy for sec-
ondary hyperparathyroidism.
The development of etelcalcetide followed a series of
basic discoveries on calcium homeostasis by Brown et al,10
who in 1993 reported on the cloning and characterization of
the calcium-sensing receptor. The first calcimimetics, includ-
ing cinacalcet, were allosteric activators of the calcium-
sensing receptor. Etelcalcetide was found to act at a site on
the calcium-sensing receptor distinct from that of cinacalcet
and to induce a sharp decline in PTH and serum calcium in
laboratory animals. Pharmacokinetic data suggested a suffi-
ciently long terminal half-life,4 making feasible the intermit-
tent administration with thrice-weekly hemodialysis.
The ability to effectively reduce PTH while simultane-
ously reducing serum concentrations of calcium and phos-
phate is widely regarded as a key differentiating attribute of
Table 1. Baseline Participant Characteristics
Characteristics
Trial A Trial B
Etelcalcetide
(n = 254)
Placebo
(n = 254)
Etelcalcetide
(n = 255)
Placebo
(n = 260)
Age, mean (SD), y 58.4 (14.6) 57.1 (14.5) 58.4 (14.6) 59.0 (13.9)
Female, No. (%) 103 (40.6) 114 (44.9) 93 (36.5) 95 (36.5)
Race, No. (%)
White 173 (68.1) 175 (68.9) 163 (63.9) 169 (65.0)
Black 72 (28.3) 69 (27.2) 64 (25.1) 80 (30.8)
Asian 5 (2.0) 3 (1.2) 13 (5.1) 6 (2.3)
Pacific Islander 0 2 (0.8) 7 (2.7) 3 (1.2)
American Indian or Alaska Native 0 0 0 0
Other or missing data 4 (1.6) 5 (2.0) 8 (3.2) 2 (0.8)
Hispanic, No. (%) 33 (13.0) 33 (13.0) 32 (12.5) 33 (12.7)
Time since initiation of dialysis,
median (IQR), y
3.95
(1.95-8.36)
3.77
(1.65-6.85)
4.00
(2.17-7.10)
3.81
(2.00-6.77)
Primary cause of end-stage renal
disease, No. (%)
Diabetes mellitus 67 (26.4) 78 (30.7) 79 (31.0) 84 (32.3)
Hypertension 63 (24.8) 65 (25.6) 64 (25.1) 58 (22.3)
Glomerulonephritis 39 (15.4) 30 (11.8) 30 (11.8) 45 (17.3)
Polycystic kidney disease 19 (7.5) 20 (7.9) 16 (6.3) 22 (8.5)
Urologic 9 (3.5) 8 (3.1) 10 (3.9) 6 (2.3)
Other 46 (18.1) 44 (17.3) 39 (15.3) 32 (12.3)
Unknown 11 (4.3) 9 (3.5) 17 (6.7) 13 (5.0)
History of kidney transplant,
No. (%)
30 (11.8) 34 (13.4) 28 (11.0) 30 (11.5)
History of cinacalcet use, No. (%) 103 (40.6) 109 (42.9) 137 (53.7) 126 (48.5)
Hemodiafiltration dialysis mode,
No. (%)
41 (16.1) 41 (16.1) 31 (12.2) 35 (13.5)
Dialysate calcium <2.5 mEq/L,
No. (%)
13 (5.1) 18 (7.1) 24 (9.4) 28 (10.8)
Albumin-corrected calcium, mean
(SD), mg/dL
9.65 (0.66 9.61 (0.60 9.63 (0.65 9.70 (0.69
Phosphate, mean (SD), mg/dL 5.95 (1.59) 5.78 (1.60) 5.76 (1.60) 5.83 (1.45)
Parathyroid hormone, pg/mL
Median (IQR) 706 (552-950) 706 (563-994) 740 (552-949) 726 (553-969)
Mean (SD) 849 (520) 820 (386) 845 (464) 852 (552)
Fibroblast growth factor 23,
median (IQR), pg/mL
6134
(1210-16 439)
3355
(811-11 939)
3181
(969-12 771)
3311
(865-12 898)
Bone-specific alkaline phosphatase,
median (IQR), μg/L
23.0
(15.2-33.9)
25.8
(17.4-38.2)
23.5
(15.4-35.0)
24.4
(16.7-36.5)
Collagen type I cross-linked
C-telopeptide, median (IQR), ng/L
2960
(1990-4090)
3100
(2290-4340)
2940
(1970-4260)
3055
(2235-4100)
Abbreviation: IQR, interquartile
range.
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Figure 2. Mean Percentage Change FromBaseline by StudyWeek in Parathyroid Hormone, Corrected Calcium, and Phosphate Concentrations
by Randomized Group in Each Trial
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calcimimetics comparedwithcalcitrioloractivevitaminDana-
logs,which stimulate calciumandphosphate absorption from
the gastrointestinal tract.11
Several observational studies have demonstrated higher
rates of mortality, cardiovascular events, and fracture in
patients with moderate to severe secondary hyperpara-
thyroidism.6-9 In an analysis of more than 40000 patients
receiving hemodialysis, Block et al7 showed that PTH con-
centrations greater than 600 pg/mL were independently
associated with a 15% higher risk of death relative to PTH
concentrations either within the Kidney Disease Outcomes
Quality Initiative target range of 150 to 300 pg/mL or 300 to
600 pg/mL; these findings were confirmed and extended by
Kalantar-Zadeh et al.8 in an even larger cohort examining
time-varying PTH concentrations. Informed by these obser-
vational studies and safety data from a pooled analysis of
short-term placebo-controlled clinical trials,12 the Evaluation
of Cinacalcet Hydrochloride Therapy to Lower Cardiovascu-
lar Events (EVOLVE) trial assessed the safety and efficacy of
the oral calcimimetic cinacalcet on death and major cardio-
vascular events in 3883 patients receiving hemodialysis with
moderate to severe secondary hyperparathyroidism.13
Roughly two-thirds of patients in both groups discontinued
oral study drug. Median PTH concentrations in cinacalcet-
treated patients declined by more than 50% during the first 6
months of the trial; median differences in PTH of 30% or
more were maintained throughout the trial despite reduced
adherence. Among patients randomized to placebo, 14% of
patients underwent parathyroidectomy and 21% started com-
mercial cinacalcet because of poorly controlled secondary
Figure 4. Median Percentage Change FromBaseline in Serum Intact Fibroblast Growth Factor 23 (FGF23) atWeeks 12 and 27 by Randomized Group
Within Each Trial
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Figure 3. Serum Intact Fibroblast Growth Factor 23 (FGF23) Concentrations at Baseline,Week 12, andWeek 27 by Randomized Group in Each Trial
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Closed circles represent means; solid lines, medians; boxes, interquartile
ranges; whiskers, 1.5 times interquartile ranges; and top and bottom open
circles, maximum andminimum observations. The following values were
excluded from the figure: in trial A, 1 (0.4%) etelcalcetide-treated and 2 (0.8%)
placebo-treated patients had FGF23 values higher than 100000 pg/mL at
baseline, 1 (0.4%) etelcalcetide-treated and 5 (2.2%) placebo-treated patients
had FGF23 values higher than 100000 pg/mL at week 12, and 2 (0.9%)
etelcalcetide-treated and 3 (1.6%) placebo-treated patients had FGF23 values
higher than 100000 pg/mL at week 27; in trial B, 2 (0.8%) etelcalcetide-
treated and 10 (3.9%) placebo-treated patients had FGF23 values higher than
100000 pg/mL at baseline, 0 etelcalcetide-treated and 5 (2.1%)
placebo-treated patients had FGF23 values higher than 100000 pg/mL at
week 12, and 2 (0.9%) 2 etelcalcetide-treated and (1.0%) placebo-treated
patients had FGF23 values higher than 100000 pg/mL at week 27.
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hyperparathyroidism. The unadjusted intention-to-treat
analysis did not show a statistically significant reduction in
the primary composite end point (relative hazard, 0.93; 95%
CI, 0.85-1.02). Adjustment for baseline characteristics
showed a 12% reduction in the relative hazard of the primary
composite end point and a 14% reduction in the relative haz-
ard of death, withmore pronounced effects observed in older
patients.13 Clinical fractures were reduced,14 as was the need
for parathyroidectomy or the development of severe, unre-
mitting hyperparathyroidism15 and development of calcific
uremic arteriolopathy (calciphylaxis).16 In aggregate, EVOLVE
suggested that correction of secondary hyperparathyroidism
in patients receiving hemodialysis might be of clinical benefit
yet highlighted the limitations of current calcimimetic
therapy with respect to sustained adherence.
Parathyroidectomy can also be used to treat severe
secondary hyperparathyroidism. A recent report on para-
thyroidectomy in 4435 patients receiving hemodialysis
demonstrated a 2% perioperative mortality rate, a 24% re-
hospitalization rate within 30 days, a 39% increase in
overall hospitalizations, and a 58% increase in hospital days
in the subsequent year.17 Thus, even among patients consid-
ered to be surgical candidates, morbidity associated with
parathyroidectomy can be substantial. Elevated PTH is fur-
ther recognized to contribute to sustained hyperphosphate-
mia, a potent risk factor consistently associated with cardio-
vascular events and mortality in patients receiving dialysis.
Patients with adequate nutritional intake and PTH levels
greater than 600 pg/mL are 3- to 5-fold more likely to have
hyperphosphatemia18; thus, efforts aimed solely at reducing
intestinal phosphate absorption are unlikely to be successful
at managing hyperphosphatemia.
The phosphatonin FGF23 elevates early in the course of
CKD19 and increases with CKD progression, commonly
reaching levels 2 orders of magnitude above normal in
patients receiving dialysis. In CKD, elevated serum concen-
trations of FGF23 have been associated with incidence and
progression of CKD, left ventricular hypertrophy, heart fail-
ure, cardiovascular events, and all-cause mortality.20-23 Ani-
mal models support a causal role of FGF23 in the develop-
ment of left ventricular hypertrophy.24 Preclinical and
clinical data suggest that calcium, phosphate, PTH, and
vitamin D all upregulate FGF23.25-27 Patients randomized to
etelcalcetide were more likely to experience substantial
lowering of FGF23 despite more frequent provision of cal-
cium and vitamin D. The clinical significance of lowering
FGF23 was supported by a post hoc analysis of EVOLVE by
Moe et al.28 Patients randomized to cinacalcet who experi-
enced at least a 30% reduction in FGF23 from baseline to
week 20 experienced nominally significant reductions in
the primary composite end point (relative hazard, 0.82; 95%
CI, 0.69-0.98), cardiovascular mortality (relative hazard,
0.66; 95% CI, 0.50-0.87), and heart failure (relative hazard,
0.69; 95% CI, 0.48-0.99).
Treatment with etelcalcetide lowered serum calcium in
the majority of patients, with overt symptomatic hypocalce-
mia reported in 7%. The calcium-lowering effect of etelcal-
cetide was evident early after treatment initiation and
reached a nadir at weeks 10 to 12 despite increased use of oral
calcium and active vitamin D analogs, along with increases in
dialysate calcium in a substantial fraction of patients. Con-
cerns regarding excessive calcium intake and a large cumula-
tive positive calcium balance in patients treated with calcimi-
metic agents are valid; additional studies are required to
assess the effects of etelcalcetide on skeletal and vascular
health. In an earlier randomized trial, patients receiving
hemodialysis treated with cinacalcet and fixed-dose vitamin
D compared with flexible doses of vitamin D alone suggested
Table 2. Treatment-Emergent Adverse Eventsa
Adverse Events
No. (%) of Participants
Trial A Trial B
Etelcalcetide
(n = 251)
Placebo
(n = 254)
Etelcalcetide
(n = 252)
Placebo
(n = 259)
Blood calcium decreaseb 153 (61.0) 21 (8.3) 168 (66.7) 31 (12.0)
Muscle spasms 30 (12.0) 18 (7.1) 28 (11.1) 16 (6.2)
Diarrhea 18 (7.2) 18 (7.1) 36 (14.3) 26 (10.0)
Nausea 31 (12.4) 13 (5.1) 23 (9.1) 19 (7.3)
Vomiting 26 (10.4) 18 (7.1) 19 (7.5) 8 (3.1)
Headache 18 (7.2) 20 (7.9) 20 (7.9) 11 (4.2)
Hypocalcaemia 18 (7.2) 1 (0.4) 17 (6.7) 0
Hypertension 12 (4.8) 17 (6.7) 19 (7.5) 12 (4.6)
Hypotension 16 (6.4) 10 (3.9) 14 (5.6) 16 (6.2)
Arteriovenous fistula site
complication
13 (5.2) 14 (5.5) 16 (6.3) 12 (4.6)
Pain in extremity 17 (6.8) 11 (4.3) 7 (2.8) 9 (3.5)
Paresthesia 13 (5.2) 3 (1.2) 11 (4.4) 0
Back pain 8 (3.2) 8 (3.1) 14 (5.6) 11 (4.2)
Upper respiratory tract infection 8 (3.2) 10 (3.9) 13 (5.2) 16 (6.2)
a Events occurring in 5% or more of
etelcalcetide-treated patients, with
1% or greater difference between
groups in at least 1 study, based on
patients who received at least 1
dose of investigational product.
Some patients may have hadmore
than 1 adverse event in each
category.
bBlood calcium decrease defined as
an albumin-corrected serum
calcium level of less than 8.3 mg/dL
that resulted in a medical
intervention.
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an attenuation of vascular and cardiac valve calcification
with calcimimetic therapy.29
Adverse events occurred in 92% of etelcalcetide-treated
and 80% of placebo-treated patients. Nausea, vomiting, and
diarrhea were more common in etelcalcetide-treated pa-
tients, as were symptoms potentially related to hypocalce-
mia, such as muscle spasms, headache, and paresthesia.
Hyperkalemia was reported twice as often in etelcalcetide-
treatedpatients; reviewof theseevents showednoconsistent
risk factors or associated events. Itmaynot be possible to dis-
entangle the effects of lower serumcalciumand etelcalcetide
itself on the QT interval. Nevertheless, physicians will need
toexercisecautionwhenusingetelcalcetideinconjunctionwith
other drugs that may prolong the QT interval. There were no
notable differences in rates of death, myocardial infarction,
stroke,orseizurebetweentheetelcalcetideandplacebogroups,
and there was only a small numerical imbalance in heart fail-
ure requiring hospitalization, although the studywas not ad-
equately powered to detect differences in event rates.
These trials have several important limitations. Although
the trials demonstrated biochemical control of secondary hy-
perparathyroidismcomparedwithplacebo, theywerenot de-
signed to assess the effects of etelcalcetide on bone architec-
ture or strength or the likelihood of fracture, an important
consequenceofsecondaryhyperparathyroidism.Moreover, the
major limitation of these trials was that they were unable to
determine whether etelcalcetide altered vascular calcifica-
tion, cardiovascular structure or function, cardiovascular
events, or other clinical outcomes, including mortality.
Conclusions
Among patients receiving hemodialysis withmoderate to se-
veresecondaryhyperparathyroidism,useofetelcalcetidecom-
paredwithplacebo resulted ingreater reduction in serumPTH
over 26 weeks. Further studies are needed to assess clinical
outcomes as well as longer-term efficacy and safety.
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